Jazz Pharmaceuticals plc
JAZZ· Nasdaq· Pharmaceutical Preparations
- Market cap
- –
- P/FCF
- –
- EV/Sales
- –
- FCF margin
- 30.4%
- ROIC, 5 yr avg
- –
- Revenue, 5 yr CAGR
- +12.5%
We record prices for the companies we cover; JAZZ is not one of them yet.
Company statistics
Profile · FY2025
- Market cap
- –
- Enterprise value
- –
- Diluted shares
- 61.0M
- Revenue
- $4.3B
- Free cash flow
- $1.3B
- Owner earnings
- $1.0B
Valuation · FY2025
- P/E
- –
- P/FCF
- –
- P/Owner earnings
- –
- EV/Sales
- –
- EV/FCF
- –
- P/B
- –
Margins · FY2025
- Gross
- –
- Operating
- -10.1%
- Net
- -8.3%
- Free cash flow
- 30.4%
- Owner earnings
- 23.6%
- Stock pay
- 6.8%
Returns
- ROIC, FY2025
- –
- ROIC, 5 yr avg
- –
- ROE, FY2025
- -8.2%
- ROE, 5 yr avg
- 0.2%
Growth (CAGR)
- Revenue, 3 yr
- 5.3%
- Revenue, 5 yr
- 12.5%
- Revenue, 9 yr
- 12.4%
- Diluted EPS, 3 yr
- –
- Diluted EPS, 5 yr
- –
- Diluted EPS, 9 yr
- –
- Free cash flow, 3 yr
- 1.4%
- Free cash flow, 5 yr
- 8.0%
- Free cash flow, 9 yr
- 9.3%
Financial health · FY2025
- Cash and investments
- $1.4B
- Total debt
- $5.4B
- Net debt
- $4.0B
- Debt/Equity
- 1.2x
- Debt/FCF
- 4.1x
Shareholder returns · FY2025
- Dividend yield
- –
- Payout ratio
- –
- Buyback yield
- –
- Shareholder yield
- –
- Share count, 5 yr
- 1.5%
Financials: ten years from the 10-Ks
Revenue
$4.3B
+12.4% a year over 9 years
FY2016FY2025
Margins
Operating-10.1%Net-8.3%
FY2025
FY2016FY2025
Free cash flow and owner earnings
Free cash flow$1.3BOwner earnings$1.0B
Free cash flow +9.3% a year
FY2016FY2025
Diluted shares
61.0M
-1.4% over 9 years, net buybacks
FY2016FY2025
Return on invested capital
–
FY2025
FY2016FY2025
Net debt (below zero)
-$4.0B
$4.0B more debt than cash
FY2016FY2025
Every figure, year by year
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| The business | ||||||||||
| Revenue | $1.5B | $1.6B | $1.9B | $2.2B | $2.4B | $3.1B | $3.7B | $3.8B | $4.1B | $4.3B |
| Revenue growth | 12.3% | 8.8% | 16.8% | 14.3% | 9.3% | 30.9% | 18.3% | 4.8% | 6.1% | 4.9% |
| Gross margin | – | – | – | – | – | – | – | – | – | – |
| Operating margin | 39.8% | 32.7% | 32.5% | 24.6% | 16.0% | 5.5% | -1.8% | 15.1% | 17.6% | -10.1% |
| Net income | $396.8M | $487.8M | $447.1M | $523.4M | $238.6M | -$329.7M | -$224.1M | $414.8M | $560.1M | -$356.1M |
| Net margin | 26.7% | 30.1% | 23.6% | 24.2% | 10.1% | -10.7% | -6.1% | 10.8% | 13.8% | -8.3% |
| Diluted EPS | $6.41 | $7.96 | $7.30 | $9.09 | $4.22 | $-5.52 | $-3.58 | $6.10 | $8.65 | $-5.84 |
| Return on invested capital? | 12.5% | – | 12.9% | – | 7.1% | – | – | – | – | – |
| Cash | ||||||||||
| Operating cash flow | $592.4M | $693.1M | $798.9M | $776.4M | $899.6M | $778.5M | $1.3B | $1.1B | $1.4B | $1.4B |
| Capital expenditure | $9.7M | $28.9M | $20.4M | $40.1M | $15.0M | $27.6M | $29.0M | $24.0M | $38.1M | $58.8M |
| Free cash flow | $582.7M | $664.1M | $778.5M | $736.3M | $884.6M | $750.9M | $1.2B | $1.1B | $1.4B | $1.3B |
| Stock-based compensation | $98.8M | $106.9M | $102.4M | $110.6M | $121.0M | $189.0M | $222.0M | $226.8M | $248.0M | $291.1M |
| Owner earnings? | $483.9M | $557.2M | $676.1M | $625.7M | $763.6M | $561.9M | $1.0B | $841.2M | $1.1B | $1.0B |
| Free cash flow per share | $9.42 | $10.83 | $12.72 | $12.79 | $15.65 | $12.58 | $19.87 | $14.82 | $20.57 | $21.27 |
| Capital allocation | ||||||||||
| Dividends paid | – | – | – | – | – | – | – | – | – | – |
| Share repurchases | $278.3M | $98.8M | $523.7M | $301.4M | $146.5M | $0 | $54.0K | $269.8M | $311.4M | $125.0M |
| Diluted shares | 61.9M | 61.3M | 61.2M | 57.5M | 56.5M | 59.7M | 62.5M | 72.1M | 66.0M | 61.0M |
| Share count change? | -1.8% | -0.9% | -0.2% | -6.0% | -1.8% | 5.6% | 4.8% | 15.2% | -8.4% | -7.6% |
| Balance sheet | ||||||||||
| Cash and equivalents | $366.0M | $386.0M | $309.6M | $637.3M | $1.1B | $591.4M | $881.5M | $1.5B | $2.4B | $1.4B |
| Short-term investments | – | – | – | – | – | – | – | – | – | – |
| Total debt | $2.0B | $1.6B | $1.6B | $1.6B | $2.1B | $6.0B | $5.7B | $5.7B | $6.1B | $5.4B |
| Net debt | $1.7B | $1.2B | $1.3B | $969.9M | $1.0B | $5.5B | $4.8B | $4.2B | $3.7B | $4.0B |
| Shareholders' equity | $1.9B | $2.7B | $2.8B | $3.1B | $3.7B | $4.0B | $3.1B | $3.7B | $4.1B | $4.3B |
Latest filings
| 2026-10-26 | 8-K | Earnings release |
| 2026-08-03 | 10-Q | Quarterly report |
| 2026-08-03 | 8-K | Earnings release |
| 2026-06-08 | DEF 14A | Proxy statement |
| 2026-05-05 | 10-Q | Quarterly report |
| 2026-05-05 | 8-K | Earnings release |
| 2026-02-24 | 10-K | Annual report |
| 2026-02-24 | 8-K | Earnings release |
| 2026-01-12 | 8-K | Earnings release |
| 2025-11-05 | 10-Q | Quarterly report |
More from our coverage
- MSFTPlatforms8.4MicrosoftThe most entrenched software franchise in the enterprise, now spending its cash flow on AI capacity; a great business we would own with a margin of safety, not at any price.Base value $410.29
- NVDAAI infrastructure8.4NVIDIAThe best business in technology at the top of its cycle: the moat is CUDA as much as silicon, but today's margins are a peak, not a floor.Base value $104.32
- AAPLHardware7.6AppleOne of the highest-quality businesses in the world growing in the low single digits; the price usually assumes more growth than the numbers show.Base value $134.27
- GOOGLPlatforms7.4AlphabetSearch pays for everything, and AI is both its biggest threat and its biggest opportunity; the price has to allow for search being worth less than it was.Base value $209.60
- NOWSoftware7.4ServiceNowA rare enterprise platform still growing above 20% with high retention; the free cash flow is real but stock pay takes a large share of it.Base value $189.13
- ADBESoftware7.4AdobeSuperb margins and a shrinking share count, priced for decline; the question is whether AI makes Adobe's tools more valuable or makes them unnecessary.Base value $449.35
